Lexicon Pharma (LXRX) Tops Q3 EPS by 2c
Tweet
Share
E-mailGet Alerts LXRX Hot Sheet
Price: $2.24 -0.88%
Revenue Growth %: -78.9%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: -78.9%
Financial Fact:
Total operating expenses: 62.65M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q3 EPS of ($0.34), $0.02 better than the analyst estimate of ($0.36). Revenue for the quarter came in at $566 thousand versus the consensus estimate of $370 thousand.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- EU proposes to curb Airbnb and short-term rentals amid housing shortage
- Goldman Sachs Downgrades Vonovia SE (VNA:DR) (VNNVF) to Neutral
- RBC Capital Reiterates Outperform Rating on Aviva PLC (AV:LN) (AVVIY)
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
